Robbie Marcus
Stock Analyst at JP Morgan
(4.28)
# 455
Out of 4,732 analysts
151
Total ratings
61%
Success rate
11.89%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NPCE NeuroPace | Maintains: Overweight | $9 → $14 | $11.97 | +16.96% | 4 | Dec 17, 2024 | |
| BVS Bioventus | Upgrades: Neutral | $12 → $13 | $10.04 | +29.48% | 3 | Dec 17, 2024 | |
| ZBH Zimmer Biomet Holdings | Upgrades: Overweight | $125 → $128 | $109.56 | +16.83% | 5 | Dec 17, 2024 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $110 | $98.66 | +11.49% | 13 | Dec 16, 2024 | |
| PODD Insulet | Maintains: Overweight | $280 → $330 | $275.81 | +19.65% | 4 | Dec 12, 2024 | |
| CBLL CeriBell | Initiates: Overweight | $32 | $21.04 | +52.09% | 1 | Nov 5, 2024 | |
| SYK Stryker | Maintains: Overweight | $375 → $420 | $383.42 | +9.54% | 8 | Oct 30, 2024 | |
| ATRC AtriCure | Maintains: Overweight | $30 → $40 | $38.47 | +3.98% | 5 | Oct 30, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $72 → $78 | $69.78 | +11.78% | 4 | Oct 25, 2024 | |
| DXCM DexCom | Maintains: Neutral | $75 → $85 | $84.38 | +0.73% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $495 → $575 | $592.64 | -2.98% | 4 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $84.74 | +6.21% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $46.63 | +7.23% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $42 | $30.98 | +35.57% | 16 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.57 | - | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $8.71 | -8.15% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $36 → $13 | $17.62 | -26.22% | 5 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $75 | $67.69 | +10.80% | 5 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $100 → $120 | $93.27 | +28.66% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $62 | $30.39 | +104.01% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $263.69 | -5.19% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $14.29 | +11.97% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $10.47 | -33.14% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $340 → $181 | $177.68 | +1.87% | 4 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $56 → $43 | $24.10 | +78.42% | 5 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $17.36 | -2.07% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $113.48 | +3.98% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $108.33 | +44.00% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $88.08 | +19.21% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $156.39 | -74.42% | 2 | May 5, 2020 |
NeuroPace
Dec 17, 2024
Maintains: Overweight
Price Target: $9 → $14
Current: $11.97
Upside: +16.96%
Bioventus
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $10.04
Upside: +29.48%
Zimmer Biomet Holdings
Dec 17, 2024
Upgrades: Overweight
Price Target: $125 → $128
Current: $109.56
Upside: +16.83%
Boston Scientific
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $98.66
Upside: +11.49%
Insulet
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $275.81
Upside: +19.65%
CeriBell
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $21.04
Upside: +52.09%
Stryker
Oct 30, 2024
Maintains: Overweight
Price Target: $375 → $420
Current: $383.42
Upside: +9.54%
AtriCure
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $38.47
Upside: +3.98%
Edwards Lifesciences
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $69.78
Upside: +11.78%
DexCom
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $84.38
Upside: +0.73%
Oct 11, 2024
Maintains: Overweight
Price Target: $495 → $575
Current: $592.64
Upside: -2.98%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $84.74
Upside: +6.21%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $46.63
Upside: +7.23%
Aug 7, 2024
Maintains: Neutral
Price Target: $44 → $42
Current: $30.98
Upside: +35.57%
Aug 7, 2024
Downgrades: Underweight
Price Target: n/a
Current: $4.57
Upside: -
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $8.71
Upside: -8.15%
May 1, 2024
Downgrades: Neutral
Price Target: $36 → $13
Current: $17.62
Upside: -26.22%
Apr 25, 2024
Maintains: Overweight
Price Target: $115 → $75
Current: $67.69
Upside: +10.80%
Mar 13, 2024
Upgrades: Overweight
Price Target: $100 → $120
Current: $93.27
Upside: +28.66%
Feb 29, 2024
Maintains: Overweight
Price Target: $40 → $62
Current: $30.39
Upside: +104.01%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $263.69
Upside: -5.19%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $14.29
Upside: +11.97%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $10.47
Upside: -33.14%
Oct 17, 2023
Maintains: Overweight
Price Target: $340 → $181
Current: $177.68
Upside: +1.87%
May 24, 2023
Downgrades: Underweight
Price Target: $56 → $43
Current: $24.10
Upside: +78.42%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $17.36
Upside: -2.07%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $113.48
Upside: +3.98%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $108.33
Upside: +44.00%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $88.08
Upside: +19.21%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $156.39
Upside: -74.42%